New research reveals ADHD isn't one-size-fits-all — covering social media's specific role, why medication rarely 'stops ...

The Food and Drug Administration (FDA) approved a new "first-in-class" medication to help manage attention deficit ...

Experts are calling for changes to ADHD care as new research raises questions about medication safety.

Military veterans with PTSD and other mental health conditions may soon be able to use psychedelic drugs to aid in their ...

The FDA has approved Simtriyo, a nonstimulant daily pill for ADHD in children, teens, and adults. Here’s more on potential ...

The FDA has approved Simtriyo (centanafadine) as the first norepinephrine, dopamine, serotonin reuptake inhibitor for adult and pediatric ADHD.

For decades, ADHD was viewed as a childhood condition that mostly affected boys. Researchers now know ADHD manifests ...

If social media is to be believed, ADHD can be managed with supplements, breathing exercises, herbal remedies, and just about ...

Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s ...

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

Merck is the pharmaceutical company that makes a medication called pembrolizumab (Keytruda), which is used to treat different ...

Once believed to be a condition that children outgrow, attention deficit hyperactivity disorder (ADHD) is now recognized as a ...